Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Galmed Pharmaceuticals ( (GLMD) ) has shared an announcement.
On January 30, 2026, Galmed Pharmaceuticals announced that it had received a notification letter from Nasdaq stating that the company is not in compliance with the exchange’s minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Capital Market. Nasdaq has granted Galmed a 180‑day grace period, from January 29, 2026 to July 28, 2026, to regain compliance, which would be achieved if its ordinary shares close at or above $1.00 for at least ten consecutive business days. The notice has no immediate effect on the listing or trading of Galmed’s shares, which will continue to trade under the symbol GLMD during the compliance period, but failure to restore the bid price in time could ultimately result in delisting, underscoring ongoing pressure on the company’s market valuation and listing status.
The most recent analyst rating on (GLMD) stock is a Hold with a $0.79 price target. To see the full list of analyst forecasts on Galmed Pharmaceuticals stock, see the GLMD Stock Forecast page.
Spark’s Take on GLMD Stock
According to Spark, TipRanks’ AI Analyst, GLMD is a Neutral.
The score is weighed down mainly by weak financial performance (no revenue, ongoing losses, and continued cash burn), with technicals also bearish as the stock trades below all major moving averages and momentum indicators remain negative. A debt-free balance sheet provides some stabilization but is not enough to offset the core operating risks.
To see Spark’s full report on GLMD stock, click here.
More about Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company based in Israel focused on developing Aramchol, primarily for liver diseases such as NASH/MASH and related fibrosis, as well as exploring certain oncological indications and cardiometabolic conditions. The company aims to expand and diversify its pipeline with innovative drug candidates aligned with its core expertise in liver, cardiometabolic and gastrointestinal oncology therapeutics.
Average Trading Volume: 2,129,159
Technical Sentiment Signal: Strong Sell
Current Market Cap: $4.45M
For detailed information about GLMD stock, go to TipRanks’ Stock Analysis page.